Jennifer J Schimmel1, Sarah Haessler1, Peter Imrey2,3, Peter K Lindenauer4,5, Sandra S Richter6, Pei-Chun Yu2, Michael B Rothberg3,7. 1. Division of Infectious Diseases, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA. 2. Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA. 3. Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA. 4. Institute for Healthcare Delivery and Population Science and Department of Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA. 5. Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, USA. 6. Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA. 7. Medicine Institute Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
BACKGROUND: The Infectious Diseases Society of America recommends pneumococcal urinary antigen testing (UAT) when identifying pneumococcal infection would allow for antibiotic de-escalation. However, the frequencies of UAT and subsequent antibiotic de-escalation are unknown. METHODS: We conducted a retrospective cohort study of adult patients admitted with community-acquired or healthcare-associated pneumonia to 170 US hospitals in the Premier database from 2010 to 2015, to describe variation in UAT use, associations of UAT results with antibiotic de-escalation, and associations of de-escalation with outcomes. RESULTS: Among 159 894 eligible admissions, 24 757 (15.5%) included UAT performed (18.4% of intensive care unit [ICU] and 15.3% of non-ICU patients). Among hospitals with ≥100 eligible patients, UAT proportions ranged from 0% to 69%. Compared to patients with negative UAT, 7.2% with positive UAT more often had a positive Streptococcus pneumoniae culture (25.4% vs 1.9%, P < .001) and less often had resistant bacteria (5.2% vs 6.8%, P < .05). Of patients initially treated with broad-spectrum antibiotics, most were still receiving broad-spectrum therapy 3 days later, but UAT-positive patients more often had coverage narrowed (38.4% vs 17.0% UAT-negative and 14.6% untested patients, P < .001). Hospital rate of UAT was strongly correlated with de-escalation following a positive test. Only 3 patients de-escalated after a positive UAT result were subsequently admitted to ICU. CONCLUSIONS: UAT is not ordered routinely in pneumonia, even in ICU. A positive UAT result was associated with less frequent resistant organisms, but usually did not lead to antibiotic de-escalation. Increasing UAT and narrowing therapy after a positive UAT result are opportunities for improved antimicrobial stewardship.
BACKGROUND: The Infectious Diseases Society of America recommends pneumococcal urinary antigen testing (UAT) when identifying pneumococcal infection would allow for antibiotic de-escalation. However, the frequencies of UAT and subsequent antibiotic de-escalation are unknown. METHODS: We conducted a retrospective cohort study of adult patients admitted with community-acquired or healthcare-associated pneumonia to 170 US hospitals in the Premier database from 2010 to 2015, to describe variation in UAT use, associations of UAT results with antibiotic de-escalation, and associations of de-escalation with outcomes. RESULTS: Among 159 894 eligible admissions, 24 757 (15.5%) included UAT performed (18.4% of intensive care unit [ICU] and 15.3% of non-ICU patients). Among hospitals with ≥100 eligible patients, UAT proportions ranged from 0% to 69%. Compared to patients with negative UAT, 7.2% with positive UAT more often had a positive Streptococcus pneumoniae culture (25.4% vs 1.9%, P < .001) and less often had resistant bacteria (5.2% vs 6.8%, P < .05). Of patients initially treated with broad-spectrum antibiotics, most were still receiving broad-spectrum therapy 3 days later, but UAT-positive patients more often had coverage narrowed (38.4% vs 17.0% UAT-negative and 14.6% untested patients, P < .001). Hospital rate of UAT was strongly correlated with de-escalation following a positive test. Only 3 patients de-escalated after a positive UAT result were subsequently admitted to ICU. CONCLUSIONS:UAT is not ordered routinely in pneumonia, even in ICU. A positive UAT result was associated with less frequent resistant organisms, but usually did not lead to antibiotic de-escalation. Increasing UAT and narrowing therapy after a positive UAT result are opportunities for improved antimicrobial stewardship.
Authors: Michael B Rothberg; Penelope S Pekow; Maureen Lahti; Oren Brody; Daniel J Skiest; Peter K Lindenauer Journal: JAMA Date: 2010-05-26 Impact factor: 56.272
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: Karl Madaras-Kelly; Makoto Jones; Richard Remington; Christina M Caplinger; Benedikt Huttner; Barbara Jones; Matthew Samore Journal: J Antimicrob Chemother Date: 2015-11-03 Impact factor: 5.790
Authors: Shawna Bellew; Carlos G Grijalva; Derek J Williams; Evan J Anderson; Richard G Wunderink; Yuwei Zhu; Grant W Waterer; Anna M Bramley; Seema Jain; Kathryn M Edwards; Wesley H Self Journal: Clin Infect Dis Date: 2019-05-30 Impact factor: 9.079
Authors: Agnar Bjarnason; Johan Westin; Magnus Lindh; Lars-Magnus Andersson; Karl G Kristinsson; Arthur Löve; Olafur Baldursson; Magnus Gottfredsson Journal: Open Forum Infect Dis Date: 2018-02-08 Impact factor: 3.835
Authors: Adam Greenfield; Kassandra Marsh; Justin Siegfried; Ioannis Zacharioudakis; Nabeela Ahmed; Arnold Decano; Maria E Aguero-Rosenfeld; Kenneth Inglima; John Papadopoulos; Yanina Dubrovskaya Journal: Open Forum Infect Dis Date: 2021-10-22 Impact factor: 3.835